Quality of life in children and teenagers with atopic dermatitis

Amaral, Cláudia Soïdo Falcão do; March, Maria de Fátima Bazhuni Pombo; Sant’Anna, Clemax Couto

doi:10.1590/s0365-05962012000500008

Cited by 44 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, most children fit the category “weak effect” on the quality of life and most guardians suffered moderate to very high effect 22 . The data reflect how the presence of a child with AD affects the quality of life, leading to a high level of compromise in the family.…”

Section: Discussionsupporting

confidence: 49%

Impacto Da Dermatite Atópica Na Qualidade De Vida De Pacientes Pediátricos E Seus Responsáveis

Campos

Araújo

Santos

et al. 2017

Rev. paul. pediatr.

View full text Add to dashboard Cite

Objective: To evaluate the impact of atopic dermatitis on the quality of life of pediatric patients in the age group of 5-16 years, and their parents, assisted at the Dermatology Department of Universidade do Estado do Pará in 2015. Methods: A cross-sectional study including 51 patients and their guardians, to whom two questionnaires about the quality of life were applied, the Children’s Dermatology Life Quality Index (CDLQI) and the Dermatitis Family Impact (DFI). To evaluate the severity of the disease, the researchers applied the Severity Scoring of Atopic Dermatitis (SCORAD) index. The Pearson Product-Moment Correlation Coefficient (PPMCC) evaluated the correlation between CDLQI, DFI, SCORAD, and the contingency coefficient C evaluated the association between the qualitative variables, considering p<0.05 significant. Results: Of the patients, 55% were female. The average age was 9.5±3.2 years, and 41% had family income up ≤1 minimum wage. The average score was 5.4±5.1 for CDLQI, 6.6±4.5 for DFI, and 28.3±19.8 for SCORAD. The correlation among the scores CDLQI, DFI, and SCORAD was significant by the PPMCC (p<0,001).Conclusions: Atopic dermatitis affects the quality of life of both children and their guardians, and indicates the importance of including the study of quality of life as a complement to clinical evaluation.

show abstract

Section: Discussionsupporting

confidence: 49%

Impacto Da Dermatite Atópica Na Qualidade De Vida De Pacientes Pediátricos E Seus Responsáveis

Campos

Araújo

Santos

et al. 2017

Rev. paul. pediatr.

View full text Add to dashboard Cite

show abstract

“…Despite this, four publications describe the use of non‐validated DFI score‐banding descriptors (Table 3). 11,26–28 …”

Section: Resultsmentioning

confidence: 99%

“… 3,6,8,10,13–28,30,32,33,35,36,39–41,44,45,47–52 The DFI has been used in 16 countries (including two multinational studies in Europe), in therapeutic interventions, descriptive studies, drug clinical trials, psychometric studies or clinical practice research studies (Table 7). 3,6,8–11,13–42,44,45,47–58 Even though the DFI is specifically for use in AD, it has been used in eight skin diseases other than AD. These include melasma, lentigo, psoriasis, ectodermal dysplasia and congenital ichthyosis 32,39,50,54 .…”

Section: Resultsmentioning

confidence: 99%

“…11,[26][27][28] Validity Twenty-six studies have correlated the DFI to other instruments, demonstrating its convergent validity (Table 4). 3,6,[8][9][10][11]14,15,25,[27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] Correlations have been reported with QoL instruments, an eczema sign severity instrument and a generic visual analogue scale; the strongest correlation demonstrated was with the Infants' Dermatitis Quality of Life Index (IDQoL). 8,29,32,33,36 Cronbach a a= 0AE90.…”

Section: Sensitivity To Changementioning

confidence: 99%

See 1 more Smart Citation

The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application

et al. 2013

View full text Add to dashboard Cite

The Dermatitis Family Impact (DFI) questionnaire is a disease-specific measure to assess the impact of atopic eczema on the quality of life (QoL) of the parents and family members of affected children. We set out to review the published literature and to collate data on the clinical and psychometric aspects of the DFI questionnaire from its development in 1998-2012, in order to create a single source of reference for users of the DFI. A literature search was performed of publications, including abstracts, describing the use of the DFI between 1998 and 2012. In total, we identified 53 publications (37 full articles and 16 abstracts) describing the use of the DFI in 50 studies. Only one study demonstrated test-retest reliability (r = 0 . 95). Three studies demonstrated internal consistency, with Cronbach α ranging from 0.85 to 0.90. Fifteen studies showed sensitivity to change of DFI scores, with significant differences between baseline and the end of the study. Twenty-six studies correlated the DFI to other objective and subjective instruments to demonstrate its construct (convergent) validity. Seventeen validated translations of the DFI have been used in 16 different countries (including two multinational studies). Nine clinical studies have assessed the effectiveness of five different topical drugs and one probiotic supplement. Two studies have assessed the effectiveness of care by dermatology nurses and dermatologists. The use of the DFI has revealed the major impact of atopic eczema on the QoL of families of affected children. The strengths of the DFI include wide international experience of its use, defined test-retest reliability, good internal consistency, sensitivity to change, and good construct (convergent) validity. Areas requiring further research include creation of validated score descriptors, assessment of minimum important clinical difference and testing of dimensionality, factor structure and differential item functioning.

show abstract

“…18 Assim, é fundamental um tratamento individualizado, integrando farmacologia e medidas socioeducativas, visando a menores danos no cotidiano dos pacientes e familiares. 18,26,27 …”

Section: Qualidade De Vidaunclassified

Abordagem da dermatite atópica na infância pelo Médico de Família e Comunidade

Guilherme

Carvalho

Diniz

et al. 2014

Rev Bras Med Fam Comunidade

View full text Add to dashboard Cite

Dermatite atópica (DA) é uma inflamação crônica e pruriginosa da pele, que acomete crianças nos primeiros anos de vida. Sua etiologia permanece pouco elucidada, mas sabe-se que ocorre uma disfunção da barreira cutânea que facilita a penetração de alérgenos/irritantes na epiderme, provocando reação inflamatória com predomínio de resposta Th2 em relação a Th1. O diagnóstico é clínico, podendo associar-se com a presença de história familiar e pregressa de atopias, como rinite e asma. A DA manifesta-se por meio de lesões eczematosas, pruriginosas, com presença de eritema, pápulas, vesículas e escamas. Os principais diagnósticos diferenciais são dermatite seborreica, dermatite de contato, psoríase e escabiose. O tratamento baseia-se na educação do paciente e de seus familiares, somado ao controle do prurido com anti-histamínicos e da inflamação com corticoides e inibidores da calcineurina. Devido à alta prevalência e impacto da DA na qualidade de vida de crianças, corrobora-se a importância do diagnóstico precoce e de uma abordagem individualizada.

show abstract

Quality of life in children and teenagers with atopic dermatitis

Cited by 44 publications

References 22 publications

Impacto Da Dermatite Atópica Na Qualidade De Vida De Pacientes Pediátricos E Seus Responsáveis

Impacto Da Dermatite Atópica Na Qualidade De Vida De Pacientes Pediátricos E Seus Responsáveis

The Dermatitis Family Impact questionnaire: a review of its measurement properties and clinical application

Abordagem da dermatite atópica na infância pelo Médico de Família e Comunidade

Contact Info

Product

Resources

About